Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
Status:
Terminated
Trial end date:
2017-02-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of oral eleclazine on mean
daytime QTcF interval after 24 weeks of treatment with elecalzine in participants with long
QT syndrome Type 3. During the single-blind treatment period (24 weeks), participants will
receive eleclazine and/or eleclazine placebo. Following the single-blind treatment period,
participants who have not permanently discontinued study drug will be eligible, at the
discretion of the investigator, to continue receiving eleclazine during an open-label
extension (OLE) phase.